C-X-C chemokine receptor type 1; C-X-C chemokine receptor type 2 (CXCR1; CXCR2)

The interleukin-8 pathway begins with the secretion of IL-8 (CXCL8), a chemokine produced by macrophages, epithelial, endothelial, and other cell types in response to inflammatory stimuli. IL-8 exerts its biological effects by binding to two G protein-coupled receptors, CXCR1 and CXCR2, primarily found on neutrophils as well as on endothelial and various immune cells. This interaction triggers signal transduction cascades that lead to chemotaxis, activation, and migration of leukocytes (mainly neutrophils) to sites of infection or injury. The pathway also promotes angiogenesis and can contribute to tumor progression by stimulating proliferation, migration, and survival of cancer and endothelial cells. Inhibiting the pathway pharmacologically is of therapeutic interest for inflammatory diseases and cancer, but such interventions carry the risk of impaired immune defense and require careful evaluation of safety and efficacy [1][2][3][4][7][8].

Other names

CXCL8neutrophil chemotactic factorInterleukin-8 receptor alpha (CXCR1)Interleukin-8 receptor beta (CXCR2)

Antagonism of CXCR1 or CXCR2 to inhibit chemotaxis and inflammatory cell recruitment; Blockade of receptor-mediated signal transduction (G protein-coupled)